Aberrant Expression of CD2 in cases with de novo Acute Myeloid Leukemia Blast Cells
DOI:
https://doi.org/10.32792/jmed.2025.29.28%20Keywords:
Acute myeloid leukaemia, Flow cytometry, Aberrant expression, CD2Abstract
Background. Acute myeloid leukaemia (AML) is a malignant clonaldisorder of immature cells in the haemopoietic hierarchical system. Flow
cytometry (FC) immunophenotyping is essential for diagnosis and subtyping
of AML. CD2 antigen is expressed on thymocytes, peripheral T cells, NKCs,
and a subpopulation of B cells; it is aberrantly expressed in a quarter of cases
of acute promyelocytic leukaemia.
Aims. This study is designed to investigate the frequency of the aberrant CD2
expression on adult AML blast cells at the initial diagnosis, and correlate their
expression with complete blood count (CBC) results, blast cells percent in
peripheral blood (PB) and bone marrow (BM), the AML subtypes,
extramedullary manifestations, and the initial response to the induction
therapy.
Methods. Thirty adult cases (> 15 years) with de novo AML were
consequently selected in the period from the 5th of October 2023 to the 10th
of March 2024. Their mean age was 38.97±18.59 yrs (18 males and 12
females). All AML cases were diagnosed according to the WHO criteria for
AML and they were diagnosed by cytomorphology and FC for suspected
cases. Aberrant antigens CD2 expressions was investigated by eight-color
(BD FACSCanto II USA) at diagnosis.
Results. CD2 was expressed on blast cells in 13.3% of AML cases. AML
cases with positive CD2 expression were younger than those with negative
expression and CD2 was expressed equally by males and females. CD2 was
significantly more expressed on leukaemic cells of M3 cases. There was no
significant correlation with any of the haematological parameters with CD2
expression. Also it appeared that there were no significant correlations
between CD2 aberrant expression with the extramedullary manifestations and
with the non-response to the induction therapy.
Conclusion. Aberrant CD2 is significantly more expressed on leukaemic
cells of M3 cases. Neither CD2 aberrant expression is found to be
significantly correlated with the age, gender, nor with the haematological
parameters, induction therapy response or extramedullary manifestations.
References
Burnett AK, Grimwade D. Acute myeloid leukaemia. In: Hoffbrand AV, Higgs DR, Keeling DM et al. editors.
Postgraduate Haematology. 7th ed. UK: Blackwell publishing 2016; 20: 352-370.
Wei MC, Dahl GV, Weinstein HJ. Acute myeloid leukemia in children. In: Hoffman R, Benz EJ, Silberstein LE et al.
editors. Hematology: Basic Principles and Practice. 6th ed. Philadelphia: Elsevier Inc. 2013; 61: 913-925.
Head D, Thompson MA. Diagnosis and classification of the acute myeloid leukemias (with discussion of the role of
the myelodysplastic syndromes in AML pathogenesis). In: Estey EH, Faderl SH, Kantarjian HM, editors. Hematologic
Malignancies: Acute Leukemias. Germany: Springer. 2008; 2: 21-46.
Bain BJ. Leukaemia Diagnosis. 5th ed. UK: Blackwell publishing; 2017.
Paraskevas F. Appendix A: Clusters of Differentiation. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F et al. editors.
Wintrobe’s Clinical Hematology. 12th ed. Philadelphia: William’s and Wilkins. 2009; 2497-2582.
Mil
Kipps TJ. Functions of T Lymphocytes: T-Cell receptors for antigen. In: Kaushansky m, Lichtman MA, Beutler E et
al. Williams Hematology. 8th ed. China: The McGraw-Hill Companies, Inc. 2010; 78: 1119-1130.
Lin P, Hao S, Medeiros LJ et al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of
PML-RARα transcripts and poorer prognosis. Am J Clin Pathol 2004; 121: 402-407.
Seiter K. Acute myeloid leukemia treatment protocols. Available at: http://emedicine.medscape.com/article/2004793
overview. (accessed 9 Feb 2024).
Chang H, Brandwein J, Qi-Long yi et al. Extramedullary infiltrates of AML are associated with CD56 expression,
q23 abnormalities and inferior clinical outcome. Leukemia Research 2004; 28(10): 1007-1011
Cheson BD, Bennett JM, Kopecky KJ et al. Revised recommendations of the International Working Group for
diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in
acute myeloid leukemia. Journal of Clinical Oncology 2003; 21(24): 4642-4649.
Dombert H. Optimal acute myeloid leukaemia therapy in 2012. Haematology Education : the education program for
the annual congress of the European Haematology Association 2012 ; 6:41-48.
Kotiah
SD.
Acute promyelocytic leukemia treatment http://emedicine.medscape.com/article/2005126-overview. (accessed 20 Dec 2023) protocols.
Available at: 2024 BD. BD FACSCanto™ II Clinical Flow Cytometry System Available at: https://www.bdbiosciences.com/en
se/products/instruments/flow-cytometers/clinical-cell-analyzers/facscanto (accessed 20 Dec 2023).
BD. Reagent Selection Tools. Available at: https://www.bdbiosciences.com/en-se/resources/reagent-selection
tools (accessed 20 Feb 2024).
BD. Products, Software & Informatics. Available at: https://www.bdbiosciences.com/en-se/products/software
(accessed 20 Dec 2023).
Bahia DM, Yamamoto M, Chauffaille ML et al. Aberrant phenotypes in acute myeloid leukemia: a high frequency and
clinical significance. Haematologica 2001; 86(8): 801-806
Lewis RE, Cruse JM, Sanders CM et al. Aberrant expression of T-cell markers in acute myeloid leukemia. Exp Mol
Pathol 2007; 83(3): 462-463.
Zheng J, Wang X, Hu Y et al. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML
cases in china. Cytometry Part B 2008; 74B: 25-29.
Auewarakul CU, Promsuwicha O, U-Pratya Y et al. Immunophenotypic profile of adult acute myeloid leukemia
(AML): analysis of 267 cases in Thailand. Asian Pac J Allergy Immunol 2003; 21: 153-160.
Jiang N, Chen X, Zhu H et al. Immunophenotype characteristics and prognosis of acute leukemia cases with cross
expressing lymphoid and myeloid lineage associated antigens (abstract). Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010;
: 1405-1409.
Lin P, Hao S, Medeiros L et al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML
RARA alpha transcripts and poorer prognosis. Am J Clin Pathol 2004: 121: 402-407.
Wang XB, Zheng JE, Gu JX et al. Correlation of immunophenotype to cytogenetics and clinical features of adult acute
myeloid leukemia. Ai Zheng 2005; 24(6): 667-671.
Ball ED, Davis RB, Griffin JD et al. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood
; 77(10): 2242-2250.
Xu F, Yin CX, Wang CL et al. Immunophenotypes and immune markers associated with acute promyelocytic leukemia
prognosis. Hindawi Publishing Corporation: Disease Markers 2014; 1-6.
Smith FO, Lampkin BC, Versteeg C et al. Expression of lymphoid-associated cell surface antigens by childhood acute
myeloid leukemia cells lacks prognostic significance. Blood 1992; 79(9): 2415-2422.
Khalidi HS, Medeiros LJ, Chang KL et al. The immunophenotype of adult acute myeloid leukemia: high frequency of
lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and
karyotypic abnormalities. Am J Clin Pathol 1998; 109: 211-220
Chang H, Yi Q. Acute myeloid leukemia with pseudo–Chédiak-Higashi anomaly exhibits a specific immunophenotype
with CD2 expression. Am J Clin Pathol 2006; 125: 791-794.
Ortolani C. Flow cytometry of hematological malignancies. 1st ed. UK: Blackwell publishing; 2011.
Bradstock K, Matthews J, Benson E et al. Prognostic value of immunophenotyping in acute myeloid leukemia. Blood
; 84(4): 1220-1225.
Ferrara F, Finizio O, De Rosa C et al. Acute myeloid leukemia expressing T cell antigens: Clinicohematological report
on six cases. Leuk Lymph 1990; 3: 217.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Haithem Ahmed Al-Rubaie Ahmed Al-Rubaie, Najwan Salih Nima, Sura Kanaan Mejeed
This work is licensed under a Creative Commons Attribution 4.0 International License.
